The TU169 monoclonal antibody specifically binds to the human Major Histocompatibility Complex (MHC) Class II HLA-DQ1 and DQ2 antigens and weakly to HLA-DQ3. HLA-DQ antigens exits as heterodimers comprised of polymorphic transmembrane HLA-DQ alpha and beta glycoproteins. HLA-DQ is expressed primarily on B cells, monocytes, macrophages, dendritic cells and activated T lymphocytes. HLA-DQ is involved in presenting peptidic antigens to CD4+ T lymphocytes. This antibody does not cross-react with HLA-DR2 and HLA-DR7. This antibody fixes complement.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.